Conference Scene: Four decades of modern pharmacogenomics: From promise to clinical utility

Pharmacogenomics

Volumn 12, Issue 9, 2011, Pages 1249-1252

  Groenen, Peter M A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PHARMACOLOGICAL BIOMARKER;

ADVERSE DRUG REACTION; CONFERENCE PAPER; DIAGNOSTIC TEST; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HUMAN; MEDICAL TECHNOLOGY; MENTAL DISEASE; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PHARMACEUTICAL CARE; PHARMACOGENETICS; PHENOTYPE; POLICY; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ECONOMICS; PERSONALIZED MEDICINE; RESEARCH; UNITED STATES;

BIOMARKERS, PHARMACOLOGICAL; BOSTON; DRUG INDUSTRY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; RESEARCH; UNITED STATES;

EID: 80052937984     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.82     Document Type: Conference Paper

References (4)

1. Hudson KL, Murphy JA, Kaufman DJ, Javitt GH, Katsanis SH, Scott J. Oversight of US genetic testing laboratories. Nat. Biotechnol. 24(9), 1083-1890 (2006).
2. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12),1144-1153 (2011).
3. Roses AD. An inherited variable poly-T repeat genotype in TOMM-40 in Alzheimer disease. Arch. Neurol. 67(5), 536-541 (2010)
4. Industry Pharmacogenomics Working Group. A number of articles on the results of the survey conducted by the I-PWG. Clin. Pharmacol. Ther. 89(4), 537-545 (2011).